Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28666947 | 0.87 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21543468 | 0.73 | HASPIN (0.39) | ALDH1A1SMN1; SMN2DHFR | |
| SCHEMBL26704890 | 0.71 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21348050 | 0.70 | POLB (0.48) | ALDH1A1SMN1; SMN2MEN1MAPTTSHR | |
| SCHEMBL21543450 | 0.70 | — | — | |
| SCHEMBL16477780 | 0.70 | ADORA2A (0.32) | — | |
| SCHEMBL29038150 | 0.70 | TSHR (0.35) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL22705029 | 0.69 | HTR7 (0.41) | ALDH1A1 | |
| SCHEMBL9186220 | 0.68 | HRH4 (0.41) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL21542868 | 0.67 | POLB (0.40) | ALDH1A1SMN1; SMN2TSHRKMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20210355125-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091481-B2 | Heterocyclic compounds, preparation and methods and uses thereof | InventisBio Co., Ltd. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20210198255-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION AND METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-07-01 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2020233592-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-11091481-B2 | Heterocyclic compounds, preparation and methods and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 1502/4885SMN1; SMN2 3435/4885MEN1 71/4885 |
| US-20210355125-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1602/4885SMN1; SMN2 3960/4885MEN1 63/4885 |
| US-20210198255-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION AND METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1502/4885SMN1; SMN2 3435/4885MEN1 71/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3126/4885SMN1; SMN2 2424/4885MEN1 1528/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | ALDH1A1 4162/4885SMN1; SMN2 3173/4885MEN1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.